Murphy Sean M, Fishman Paul A, McPherson Sterling, Dyck Dennis G, Roll John R
Department of Health Policy and Administration, Washington State University, P.O. Box 1495, Spokane, WA 99210-1495, USA.
Group Health Research Institute, Seattle, WA 98101, USA.
J Subst Abuse Treat. 2014 Mar;46(3):315-9. doi: 10.1016/j.jsat.2013.09.003. Epub 2013 Oct 25.
This study assessed the social, demographic and clinical determinants of whether an opioid-dependent patient received buprenorphine versus an alternative therapy. A retrospective cohort analysis of opioid-dependent adults enrolled in Group Health Cooperative between January 1, 2006 and December 1, 2010 was performed. Increasing the number of physicians with DATA waivers in a region and living in a relatively-populated area increased the likelihood of being treated with buprenorphine, indicating that lack of access is a potential barrier. Comorbidity also appeared to be a factor in receipt of treatment, with the effect varying by diagnosis. Finally, patients with an insurance plan allowing health services to be sought from any provider, with increased cost sharing, were significantly more likely to receive buprenorphine, implying that patient demand is a factor. Programs integrating patient education, physician training, and support from addiction specialists would be likely facilitators of increasing access to this cost-effective treatment.
本研究评估了阿片类药物依赖患者接受丁丙诺啡治疗而非替代疗法的社会、人口统计学和临床决定因素。对2006年1月1日至2010年12月1日期间参加健康合作组织的阿片类药物依赖成年人进行了回顾性队列分析。某地区持有《药物成瘾治疗法》豁免权的医生数量增加以及居住在人口相对密集的地区,会增加接受丁丙诺啡治疗的可能性,这表明难以获得治疗是一个潜在障碍。合并症似乎也是接受治疗的一个因素,其影响因诊断而异。最后,拥有允许从任何医疗机构寻求医疗服务且费用分担增加的保险计划的患者,接受丁丙诺啡治疗的可能性显著更高,这意味着患者需求是一个因素。整合患者教育、医生培训以及成瘾专家支持的项目可能会促进人们更容易获得这种具有成本效益的治疗。